

CONTENTS

CHAPTER	Page No.
1. Introduction	1
2. Review of Literature	9
2.1. Human immunodeficiency viruses (HIV)	9
2.1.1. Replicative cycle of HIV-1 showing the sites of action of available antiretroviral agents	13
2.1.2. How the virus causes disease	16
2.1.3. History of Antiretroviral therapy	18
2.1.4. Principles of HIV chemotherapy	22
2.1.5. Structures and Mechanism of nucleoside and nucleotide reverse transcriptase inhibitors	32
2.1.6. Intracellular activation of nucleoside analog reverse transcriptase Inhibitors	36
2.1.7. Epidemiology	38
2.2. Drug Profiles	41
2.2.1. Lamivudine	41
2.2.2. Chemical Data	42
2.2.3. Pharmacokinetic Data	42
2.2.4. Mechanism of action and Resistance	43
2.2.5. Drug interactions and Precautions	44
2.2.6. Therapeutic uses	44
2.3. Zidovudine	45
2.3.1. Chemistry and Anti-viral activity	45
2.3.2. Chemical Data	46
2.3.3. Pharmacokinetic Data	47
2.3.4. Absorption, Distribution, and Elimination	47
2.3.5. Mechanism of action and Resistance	48

2.3.6. Untoward Effects	50
2.3.7. Drug interactions and Precautions	51
2.3.8. Therapeutic uses	52
2.4. Nevirapine	53
2.4.1. Chemical data	54
2.4.2. Pharmacokinetic Data	54
2.4.3. Mechanism of actions	55
2.4.4. Drug interactions and Precautions	55
2.4.5. Therapeutic uses	56
2.5. Chromatography	79
2.5.1. Types of HPLC	82
2.5.2. Reversed phase liquid Chromatography	82
2.5.3. Stationary phases for reversed phase liquid Chromatography	82
2.5.4. Types of elution mode in RP-HPLC	84
2.5.5. Mobile Phase	84
2.5.6. Validation of Analytical Procedures	84
2.5.7. Terminology	85
2.5.8. Hypothesis Tests	88
2.5.9. Strategy for Validation	91
2.5.10. Linearity and Selection of the Calibration Model	96
2.5.11. Problems in Analysis	96
2.5.12. Sequence of the Linearity Evaluation	98
2.5.13. Visual Evaluation	99
2.5.14. Outliers	99
2.5.15. Linearity experiments	101
2.5.16. Precision and Bias	102
2.5.17. Sequence of the Evaluation	104
2.5.18. Precision Estimates	104
2.5.19. Precision Experiments	107
2.5.20. Standard Addition	109

2.5.21. Regression Analysis	110
2.5.22. Specificity	111
2.5.23. Critique on the current practice	111
2.5.24. Recommended Approach	112
2.5.25. Range (Assay)	114
2.5.26. Quantitation limit (LOQ)	115
2.5.27. Detection limit (LOD)	115
2.5.28. Chromatographic Methods	116
2.5.29. Analyte Stability in the Matrix	117
2.5.30. Test Conditions	118
2.5.31. Robustness	119
3. Aims and Objectives	
4. Materials & Methods	131
4.1. Chemicals and Reagents	131
4.2. Instrumentation	131
4.3. Chromatographic System and Conditions	131
4.4. Preparation of Standard Stock Solutions	132
4.4.1. Linearity for Lamivudine	132
4.4.2. Linearity for Zidovudine	133
4.4.3. Linearity for Nevirapine	133
4.5.1. Application of the developed Method to Drug formulations for Lamivudine	134
4.5.2. Application of the developed Method to Drug formulations for Zidovudine	135
4.5.3. Application of the developed Method to Drug formulations for Nevirapine	136
4.6. Method Validation	137
4.6.1. Linearity and Range	137
4.6.2. Precision	137
4.6.3. Intermediate Precision	137

4.6.4. Method Precision	137
4.6.5. Accuracy	137
4.6.6. Reproducibility/Ruggedness	137
4.6.7. Specificity	138
4.6.9. System suitability tests	138
4.6.10. LOD and LOQ	139
4.7. Stability Indicating Studies	139
4.7.1. Forced degradation Studies for Lamivudine	139
4.7.2. Forced degradation Studies for Zidovudine	142
4.7.3. Forced degradation Studies for Nevirapine	145
4.8. Application of the developed Method to Pharmacokinetic Studies	148
4.8.1. <i>In-vitro</i> dissolution Studies from tablet dosage form for Lamivudine	150
4.8.1. <i>In-vitro</i> dissolution Studies from tablet dosage form for Zidovudine	151
4.8.1. <i>In-vitro</i> dissolution Studies from tablet dosage form for Nevirapine	158
4.9. <i>In-vivo</i> Pharmacokinetic Animal Studies	153
4.9.1. <i>In-vivo</i> Pharmacokinetic Animal Studies- for Lamivudine	153
4.9.2. <i>In-vivo</i> Pharmacokinetic Animal Studies- for Zidovudine	154
4.9.3. <i>In-vivo</i> Pharmacokinetic Animal Studies- for Nevirapine	156
5. Results	158
5.1. Analysis of Drugs	158
5.1.1. Description	158
5.1.2. Melting point	158
5.1.3. Solubility	158
5.1.4. UV scan	158
5.1.5. Infra red spectra	158
5.1.6. Preliminary Injection of Drugs	159
5.1.7. Scan test	160
5.1.7. Effect of Incorporating methanol	160
5.1.8. Effect of changing the flow rate	160
5.2. Validation parameters	162

5.2.1. Linearity and range	162
5.2.2. Precision	165
5.2.3. Intermediate Precision	167
5.2.4. Method – Precision	168
5.2.5. Regression analysis	170
5.2.6. Accuracy	171
5.2.6. Robustness	173
5.2.7. Ruggedness	176
5.2.8. Specificity	178
5.2.9. System suitability	178
5.2.10. Limit of detection (LOD) and limit of quantitation (LOQ)	180
5.2.11. Application of Method to Marketed formulations Lamivudine	181
5.2.12. Application of Method to Marketed formulations of Zidovudine	182
5.5.12. Application of Method to Marketed formulations of Nevirapine	183
5.3. Stability Indicating Studies	184
5.3.1. Stability Indicating Studies for Lamivudine	184
5.3.2. Stability Indicating Studies for Zidovudine	189
5.3.3. Stability Indicating Studies for Nevirapine	194
5.4. Calculation for Pharmacokinetic data's	199
5.4.1. <i>In-vitro</i> Pharmacokinetic Drug Release of Lamivudine	201
5.4.2. <i>In-vitro</i> Pharmacokinetic Drug Release of Zidovudine	206
5.4.3. <i>In-vitro</i> Pharmacokinetic Drug Release of Nevirapine	212
5.5.1. <i>In-vivo</i> Pharmacokinetic Animal Studies for Lamivudine	217
5.5.2. <i>In-vivo</i> Pharmacokinetic Animal Studies for Zidovudine	223
5.5.3. <i>In-vivo</i> Pharmacokinetic Animal Studies for Nevirapine	230
5.5.4. IR spectrum of Standard Lamivudine	238
5.5.5. IR spectrum of Standard Zidovudine	239
5.5.6. IR spectrum of Standard Nevirapine	240
5.5.7. Method Development	241
5.5.8. Validation	267

5.5.9. Assay	303
5.6. Lamivudine Stability Indicating Studies	315
5.6.1. Base Stress Studies	315
5.6.2. Acid Stress	318
5.6.3. Peroxide Stress	321
5.6.4. Photolytic Studies by UV light for Lamivudine	325
5.6.5. Thermal Stress of Lamivudine	329
5.7 Zidovudine Stability Indicating Studies	335
5.7.1. Base Stress Studies	335
5.7.2. Acid Stress	337
5.7.3. Peroxide Stress	339
5.7.4. Photolytic Studies by UV light for Zidovudine	343
5.7.5. Thermal Stress Condition of Zidovudine	350
5.8. Nevirapine Stability Indicating Studies	358
5.8.1. Base Stress Studies	358
5.8.2. Acid Stress	360
5.8.3. Peroxide Stress	361
5.8.4. Photolytic Studies by UV light for Zidovudine	365
5.8.5. Thermal Stress condition of Zidovudine	371
5.9. <i>In-vitro</i> Studies	377
5.9.1. <i>In-vitro</i> Pharmacokinetics Release Studies for Lamivudine at pH-1.2	377
5.9.2. <i>In-vitro</i> Pharmacokinetics Release Studies for Lamivudine <i>in-vitro</i> at pH 6.8	381
5.9.3. <i>In-vitro</i> Pharmacokinetics Release Studies for Lamivudine <i>in-vitro</i> at pH 7.2	385
5.9.4. <i>In-vitro</i> Pharmacokinetics Release Studies for Zidovudine <i>in-vitro</i> at pH 1.2	389
5.9.5. <i>In-vitro</i> Pharmacokinetics Release Studies for Zidovudine <i>in-vitro</i> at pH 6.8	393

5.13.10. <i>In-vivo</i> Drug Release Studies of Nevirapine in Rabbits Group A	463
5.13.11. <i>In -vivo</i> Drug Release Studies of Nevirapine in Rabbits Group B	465
5.13.12. <i>In-vivo</i> Drug Release Studies of Nevirapine in Rabbits Group C	467
5.13.13. <i>In-vivo</i> Drug Release Studies of Nevirapine in Rabbits Group D	469
6. Discussion	471
7. Conclusion	480
References	
Glossary	
Publication	
Certificates	
Addendum / Corrigendum	1-11